BioCentury
ARTICLE | Clinical News

Tiziana gains on milciclib cancer data

April 21, 2017 8:55 PM UTC

Tiziana Life Sciences plc (LSE:TILS) jumped 30.50p (16%) to 219p on Friday after announcing data from a Phase I trial of milciclib maleate (PHA-848125AC) to treat refractory solid tumors.

In 14 evaluable patients, milciclib plus gemcitabine led to a disease control rate (DCR) of 36%, including one partial response in a patient with non-small cell lung cancer (NSCLC) and four cases of stable disease for up to 14 months. Patients received once-daily 45, 60 or 80 mg/m^2 oral milciclib for seven days on and seven days off in each four-week cycle. Data were published in Cancer Chemotherapy and Pharmacology...